急性骨髄性白血病患者に併発したカンジダ性肝脾膿瘍に対するリボソーム型アンホテリシンBの使用経験 (症例報告)

長谷川 太郎; 日吉 基文; 青山 泰孝; 阪本 親彦; 太田 健介; 山根 孝久; 日野 雅之; 巽 典之

doi:10.11150/kansenshogakuzasshi1970.72.635

Treatment of Hepatosplenic Candidiasis with Liposomal Amphotericin B in a Patient with Acute Leukemia; A Case Report of the Experience of Use of Liposomal Amphotericin B

Taro HASEGAWA, Motofumi HIYOSHI, Yasutaka AOYAMA, Chikahiko SAKAMOTO, Kensuke OHTA, Takahisa YAMANE, Masayuki HINO, Noriyuki TATSUMI

Author information

Taro HASEGAWA
Departments of Laboratory Medicine and Clinical Hematology, Osaka City University Medical School
Motofumi HIYOSHI
Departments of Laboratory Medicine and Clinical Hematology, Osaka City University Medical School
Yasutaka AOYAMA
Departments of Laboratory Medicine and Clinical Hematology, Osaka City University Medical School
Chikahiko SAKAMOTO
Departments of Laboratory Medicine and Clinical Hematology, Osaka City University Medical School
Kensuke OHTA
Departments of Laboratory Medicine and Clinical Hematology, Osaka City University Medical School
Takahisa YAMANE
Departments of Laboratory Medicine and Clinical Hematology, Osaka City University Medical School
Masayuki HINO
Departments of Laboratory Medicine and Clinical Hematology, Osaka City University Medical School
Noriyuki TATSUMI
Departments of Laboratory Medicine and Clinical Hematology, Osaka City University Medical School

Keywords: liposomal amphotericin B, hepatosplenic abscess, acute myelogenous leukemia, candidiasis

JOURNAL FREE ACCESS

1998 Volume 72 Issue 6 Pages 635-637

DOI https://doi.org/10.11150/kansenshogakuzasshi1970.72.635

Details

Abstract

We report a 26-year-old male patient with acute myelocytic leukemia and hepatosplenic candidiasis during his clinical course. His hepatosplenic candidiasis was refractoty to itraconazole and fluconazol. He developed serious side-effect such as renal dysfunction, when conventional amphotericin B was given.
Then he was treated with liposomal amphotericin B (Abelcet^®). This therapy was safe and effective for him. He was able to be treated with 3075 mg of a liposomal amphotericin B. Thiswas ten times as much as the dose of conventional amphotericin B which was given earlier until amphotericin B was stopped because of renal dysfunction.
Liposomal amphotericin B seems to be a safe and effective therapy for systemic fungal infectin and should be considered more in Japan.

Corresponding author

Register with J-STAGE for free!